This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (45)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Health Policy  • Quality of Care  • Quality of Care, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

NICE and the British National Health Service

Steven D. Pearson, MD, MSc; Michael D. Rawlins, MD

JAMA. 2005;294:2618-2622.

The National Institute for Health and Clinical Excellence (NICE) was established as a part of the British National Health Service in 1999 to set standards for the adoption of new health care technologies and the management of specific conditions. In doing so it was required explicitly to take into account both clinical effectiveness and cost-effectiveness. This article describes how NICE has responded to the challenge and considers whether its experience of balancing quality, innovation, and value for money holds policy lessons for the United States.

Author Affiliations: National Institute for Clinical Excellence, London, England (Drs Pearson and Rawlins); Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass (Dr Pearson); and Wolfson Unit of Clinical Pharmacology, University of Newcastle, Newcastle upon Tyne, England (Dr Rawlins).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Cost-effectiveness Analysis in the United States
Matthew Wynia
JAMA. 2006;295(23):2722.
EXTRACT | FULL TEXT  

Cost-effectiveness Analysis in the United States—Reply
Steven D. Pearson
JAMA. 2006;295(23):2722-2723.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Drug Prices and Value for Money: The Australian Pharmaceutical Benefits Scheme
David A. Henry, Suzanne R. Hill, and Anthony Harris
JAMA. 2005;294(20):2630-2632.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Six-Month Prophylaxis Is Cost Effective in Transplant Patients at High Risk for Cytomegalovirus Infection
Luan et al.
J. Am. Soc. Nephrol. 2009;20:2449-2458.
ABSTRACT | FULL TEXT  

Patient-Reported Recovery After Abdominal and Pelvic Surgery Using the Convalescence and Recovery Evaluation (CARE): Implications for Measuring the Impact of Surgical Processes of Care and Innovation
Hedgepeth et al.
SURG INNOV 2009;16:243-248.
ABSTRACT  

Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement.
Messori et al.
J. Thorac. Cardiovasc. Surg. 2009;138:480-485.
ABSTRACT | FULL TEXT  

The cost-effectiveness of induction immunosuppression in kidney transplantation
Morton et al.
Nephrol Dial Transplant 2009;24:2258-2269.
ABSTRACT | FULL TEXT  

A model for NICE in the US
Ferner and McDowell
BMJ 2009;338:b2221-b2221.
FULL TEXT  

Chronic Care In The English National Health Service: Progress And Challenges
Ham
Health Aff (Millwood) 2009;28:190-201.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Stroke Unit Care Followed by Early Supported Discharge
Saka et al.
Stroke 2009;40:24-29.
ABSTRACT | FULL TEXT  

Cost-effectiveness of the Australian National Tobacco Campaign
Hurley and Matthews
Tobacco Control 2008;17:379-384.
ABSTRACT | FULL TEXT  

Choice of Comparator in Active Control Trials of New Drugs
van Luijn et al.
The Annals of Pharmacotherapy 2008;42:1605-1612.
ABSTRACT | FULL TEXT  

Clinical priority setting
Norheim
BMJ 2008;337:a1846-a1846.
FULL TEXT  

The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004
Harris et al.
Med Decis Making 2008;28:713-722.
ABSTRACT  

The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
Schlander
J. Med. Ethics 2008;34:534-539.
ABSTRACT | FULL TEXT  

NICE: Managing conflict
Iliffe and Manthorpe
JRSM 2008;101:2-3.
FULL TEXT  

Controversies in Using Lapatinib at Reduced Dosage With Food
Trippoli
JCO 2007;25:5333-5333.
FULL TEXT  

The Value Meal: Effect of Food on Lapatinib Bioavailability
Rahman et al.
JCO 2007;25:5333-5334.
FULL TEXT  

Essential Elements of a Technology and Outcomes Assessment Initiative
Emanuel et al.
JAMA 2007;298:1323-1325.
FULL TEXT  

Simplified Pharmacoeconomics of Critical Care and Severe Sepsis
Ernst et al.
J Intensive Care Med 2007;22:283-293.
ABSTRACT  

Medicare And Cost-Effectiveness Analysis: Time To Ask The Taxpayers
Gold et al.
Health Aff (Millwood) 2007;26:1399-1406.
ABSTRACT | FULL TEXT  

Why Well-Insured Patients Should Demand Value-Based Insurance Benefits
Denny et al.
JAMA 2007;297:2515-2518.
FULL TEXT  

Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis
Garrison et al.
Health Aff (Millwood) 2007;26:684-695.
ABSTRACT | FULL TEXT  

Should NICE evaluate complementary and alternative medicine?
Franck et al.
BMJ 2007;334:506-506.
FULL TEXT  

Interpreting the Economic Literature in Oncology
Grusenmeyer and Wong
JCO 2007;25:196-202.
ABSTRACT | FULL TEXT  

Evidence, Appropriateness, And Technology Assessment In Cardiology: A Case Study Of Computed Tomography
Redberg
Health Aff (Millwood) 2007;26:86-95.
ABSTRACT | FULL TEXT  

Can A Center For Comparative Effectiveness Information Succeed? Perspectives From A Health Care Company
Buto and Juhn
Health Aff (Millwood) 2006;25:w586-w588.
ABSTRACT | FULL TEXT  

The Emerging Market Dynamics Of Targeted Therapeutics
Calfee and DuPre
Health Aff (Millwood) 2006;25:1302-1308.
ABSTRACT | FULL TEXT  

Cost-effectiveness Analysis in the United States
Wynia
JAMA 2006;295:2722-2722.
FULL TEXT  

Drug Prices and Value for Money: The Australian Pharmaceutical Benefits Scheme
Henry et al.
JAMA 2005;294:2630-2632.
FULL TEXT